Dynavax Technologies Co. (NASDAQ:DVAX) Shares Sold by PDT Partners LLC

PDT Partners LLC cut its position in Dynavax Technologies Co. (NASDAQ:DVAX - Free Report) by 11.6% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 314,865 shares of the biopharmaceutical company's stock after selling 41,250 shares during the period. PDT Partners LLC owned about 0.24% of Dynavax Technologies worth $4,021,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds have also recently modified their holdings of the company. Dimensional Fund Advisors LP raised its holdings in Dynavax Technologies by 4.4% during the fourth quarter. Dimensional Fund Advisors LP now owns 4,067,951 shares of the biopharmaceutical company's stock valued at $51,948,000 after acquiring an additional 171,933 shares during the period. Renaissance Technologies LLC lifted its holdings in Dynavax Technologies by 1.8% in the 4th quarter. Renaissance Technologies LLC now owns 2,355,278 shares of the biopharmaceutical company's stock worth $30,077,000 after purchasing an additional 41,000 shares in the last quarter. Northern Trust Corp boosted its stake in Dynavax Technologies by 10.3% in the 4th quarter. Northern Trust Corp now owns 1,457,848 shares of the biopharmaceutical company's stock worth $18,617,000 after purchasing an additional 135,826 shares during the period. Charles Schwab Investment Management Inc. grew its holdings in Dynavax Technologies by 2.9% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 1,155,080 shares of the biopharmaceutical company's stock valued at $14,750,000 after buying an additional 32,347 shares in the last quarter. Finally, Bank of Montreal Can raised its position in shares of Dynavax Technologies by 0.5% during the fourth quarter. Bank of Montreal Can now owns 1,082,180 shares of the biopharmaceutical company's stock valued at $13,819,000 after buying an additional 5,099 shares during the last quarter. 96.96% of the stock is currently owned by institutional investors.

Dynavax Technologies Trading Down 1.3 %

Shares of DVAX traded down $0.15 during mid-day trading on Friday, reaching $11.33. 1,750,419 shares of the company's stock traded hands, compared to its average volume of 2,203,668. Dynavax Technologies Co. has a 12 month low of $9.74 and a 12 month high of $14.63. The company has a debt-to-equity ratio of 0.33, a current ratio of 13.23 and a quick ratio of 12.34. The stock has a market cap of $1.39 billion, a P/E ratio of 62.94 and a beta of 1.26. The stock's 50-day moving average is $12.59 and its two-hundred day moving average is $12.59.

Dynavax Technologies (NASDAQ:DVAX - Get Free Report) last released its earnings results on Thursday, February 20th. The biopharmaceutical company reported $0.05 earnings per share for the quarter, hitting analysts' consensus estimates of $0.05. The business had revenue of $72.03 million for the quarter, compared to analyst estimates of $72.70 million. Dynavax Technologies had a return on equity of 4.22% and a net margin of 9.85%. Research analysts forecast that Dynavax Technologies Co. will post 0.32 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of brokerages have recently weighed in on DVAX. The Goldman Sachs Group cut their price objective on Dynavax Technologies from $12.00 to $10.00 and set a "sell" rating for the company in a research report on Thursday, April 17th. StockNews.com raised Dynavax Technologies from a "hold" rating to a "buy" rating in a research note on Monday, February 24th. HC Wainwright reiterated a "buy" rating and set a $31.00 target price on shares of Dynavax Technologies in a research report on Friday, February 21st. Finally, William Blair restated an "outperform" rating on shares of Dynavax Technologies in a research report on Friday, February 21st.

About Dynavax Technologies

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.